Oncopeptides (BATS-CHIXE:ONCOS) - Aandelenkoers, Nieuws & Analyse

ONCOS Overzicht aandelen

A biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Meer informatie

ONCOS fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 87.42% per jaar groeien

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( SEK9M )

Aandelen zijn zeer illiquide

Heeft minder dan 1 jaar cash runway

Heeft geen betekenisvolle marktkapitalisatie ( SEK942M )

+ 2 meer risico's

Oncopeptides AB (publ) Concurrenten

Tissue Regenix Group

AIM:TRX

UK£41.0m

e-therapeutics

AIM:ETX

UK£52.6m

Faron Pharmaceuticals Oy

AIM:FARN

UK£177.9m

Bioventix

AIM:BVXP

UK£193.1m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Oncopeptides
Historische aandelenkoersen
Huidige aandelenkoers	SEK 11.13
52 Week Hoogtepunt	SEK 42.51
52 Week Laag	SEK 11.01
Bèta	-0.61
11 maand verandering	0%
3 maanden verandering	-1.59%
1 Jaar Verandering	n/a
33 jaar verandering	-91.38%
5 jaar verandering	n/a
Verandering sinds IPO	-91.40%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	ONCOS	GB Biotechs	GB Markt
7D	0%	0.8%	0.4%
1Y	n/a	-13.1%	7.9%

Rendement versus industrie: Er zijn onvoldoende gegevens om te bepalen hoe ONCOS presteerde ten opzichte van de UK Biotechs.

Rendement versus markt: Er zijn onvoldoende gegevens om te bepalen hoe ONCOS presteerde ten opzichte van de UK markt.

Prijsvolatiliteit

Is ONCOS's price volatile compared to industry and market?
ONCOS volatility
ONCOS Average Weekly Movement	n/a
Biotechs Industry Average Movement	7.4%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.4%
10% least volatile stocks in GB Market	2.6%

Stabiele aandelenkoers: ONCOS heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van ONCOS in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2000	59	Monica Shaw	www.oncopeptides.com/sv

Oncopeptides AB (publ) Samenvatting

Hoe verhouden de winst en inkomsten van Oncopeptides zich tot de beurswaarde?
ONCOS fundamentele statistieken
Marktkapitalisatie	SEK 942.15m
Inkomsten(TTM)	-SEK 310.39m
Inkomsten(TTM)	SEK 9.48m

99.4x

P/S-verhouding

-3.0x

Koers/Winstverhouding

Is ONCOS overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ONCOS resultatenrekening (TTM)
Inkomsten	SEK 9.48m
Kosten van inkomsten	SEK 17.00k
Brutowinst	SEK 9.46m
Overige uitgaven	SEK 319.85m
Inkomsten	-SEK 310.39m

Laatst gerapporteerde inkomsten

Mar 31, 2023

Volgende inkomensdatum

Aug 10, 2023

Winst per aandeel (EPS)	-3.29
Brutomarge	99.82%
Nettowinstmarge	-3,274.49%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde ONCOS op de lange termijn?

Bekijk historische prestaties en vergelijking

ONCOS Overzicht aandelen

Beloningen

Risicoanalyse

Oncopeptides AB (publ) Concurrenten

AIM:TRX

UK£41.0m

AIM:ETX

UK£52.6m

AIM:FARN

UK£177.9m

AIM:BVXP

UK£193.1m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

An undisclosed buyer acquired an 9.166336% stake in Oncopeptides AB (publ) (OM:ONCO) from Industrifonden for SEK 22.4 million.

Oncopeptides AB (publ) Presents New Data Highlighting Treatment Benefits of Pepaxti in High-Risk Multiple Myeloma Patients at the COMy Congress

Oncopeptides AB (Publ) Provides Sales Guidance for the First Quarter of 2024

Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 300 million.

Oncopeptides AB (publ), Annual General Meeting, May 22, 2024

Oncopeptides Announces European Commission Decides to Formally Approve its Application to EMA for Extended Indication for Pepaxti into Earlier Lines

Recent updates

An undisclosed buyer acquired an 9.166336% stake in Oncopeptides AB (publ) (OM:ONCO) from Industrifonden for SEK 22.4 million.

Oncopeptides AB (publ) Presents New Data Highlighting Treatment Benefits of Pepaxti in High-Risk Multiple Myeloma Patients at the COMy Congress

Oncopeptides AB (Publ) Provides Sales Guidance for the First Quarter of 2024

Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 300 million.

Oncopeptides AB (publ), Annual General Meeting, May 22, 2024

Oncopeptides Announces European Commission Decides to Formally Approve its Application to EMA for Extended Indication for Pepaxti into Earlier Lines

Oncopeptides AB (publ) to Report Q3, 2024 Results on Nov 07, 2024

Oncopeptides Selects to Present Additional Data from Ocean Study

Oncopeptides AB (publ) to Report Q2, 2024 Results on Aug 14, 2024

Oncopeptides AB (publ) Announces the Nomination Committee

Oncopeptides AB (publ) to Report Q1, 2024 Results on May 03, 2024

Oncopeptides AB (publ) to Report Fiscal Year 2023 Final Results on Apr 22, 2024

Oncopeptides AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024

Oncopeptides AB (Publ) Announces Positive Opinion on Type II Variation to Extend the Therapeutic Indication of Pepaxti Based on Ocean Trial Results

Oncopeptides AB (publ) Appoints Henrik Bergentoft as Chief Financial Officer

Oncopeptides AB (publ) Announces Sofia Heigis to Move from the CCO Role to CEO Role

Holger Lembrér Will Leave Oncopeptides as Chief Financial Officer

Insufficient new directors

Insufficient new directors

Oncopeptides AB (publ) to Report Q2, 2023 Results on Aug 10, 2023

Oncopeptides AB (Publ) Announces Chief Financial Officer Changes

Oncopeptides AB (publ) Announces Jakob Lindberg Assumes Chief Scientific Officer

Oncopeptides AB (Publ) Announces Executive Changes

Oncopeptides AB (publ) Announces Nomination Committee Appointments

Oncopeptides AB (publ) to Report Fiscal Year 2022 Final Results on Apr 25, 2023

Oncopeptides Provides Update on Pepaxto US Marketing Authorization

Insufficient new directors

Oncopeptides AB (Publ) Announces Pepaxti Has Been Granted Marketing Authorization in the Uk

Oncopeptides AB (Publ) Announces the Market Potential for Pepaxti in Europe

Oncopeptides AB (publ), Annual General Meeting, May 25, 2023

Insufficient new directors

Oncopeptides AB (publ) Announces Data from the Phase 3 Lighthouse Study

Insufficient new directors

Oncopeptides AB (publ) Starts Commercialization of Pepaxti in Europe - Germany First Market

Oncopeptides AB (publ) Provides Update from Meeting with Advisory Committee ODAC

Insufficient new directors

Oncopeptides AB (Publ) Receives SEK 5 Million Grant for Nk-Cell Engager Project in Multiple Myeloma

European Commission Approves Oncopeptides' Pepaxti for the Treatment of Patients with Relapsed Refractory Multiple Myeloma

Forecast to breakeven in 2024

Insufficient new directors

Oncopeptides AB (Publ) Issues A Positive Opinion Recommending Full Approval of Oncopeptides Peti in Eu for Patients with Tr Triple Class Refractory Multiple Myeloma

Oncopeptides AB (Publ) Announces That the European Medicines Agency´S Committee for Medicinal Products for Human Use

Insufficient new directors

Insufficient new directors

Insufficient new directors

Oncopeptides AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023

Oncopeptides Rescinds Voluntary Withdrawal of Pepaxto in the US – No Intent to Market in the US at This Time

Oncopeptides AB (Publ) Announces Data from Phase 3 Ocean Study Published in the Lancet Haematology

Oncopeptides AB (Publ) Presents Phase 3 Ocean Study Results At the IMW Meeting

Oncopeptides AB (publ) Presents New Data from OCEAN and PORT Study - Abstracts Online

Deputy CEO & CFO recently bought kr82k worth of stock

No longer forecast to breakeven

Oncopeptides' Pepaxto Receives Specific C-Code and Pass-Through Payment Status Further Streamlining Reimbursement in Hospital Sites of Care

Forecast to breakeven in 2023

Insider recently bought kr200k worth of stock

Oncopeptides AB Announces Positive Topline Results from the Head-To-Head Phase 3 Ocean Study Evaluating the Efficacy and Safety of Melflufen

Forecast breakeven pushed back to 2024

Oncopeptides AB (Publ) Presents Clinical Abstracts on Melflufen At the 2021 American Society of Clinical Oncology

Oncopeptides AB (publ) Presents New Clinical and Preclinical Melflufen Data at the Upcoming European Hematology Association Meeting